Open Access Open Access  Restricted Access Subscription Access

Etiology, Patho Physiology, Diagnosis, Differential Diagnosis as well as Treatment of Hepatitis C And A Comprehensive Report

Sony Sharlet E, Muralinath E., Guruprasad M., Mohan Naidu K., Srinivas Prasad Ch., Jayinder Paul Singh. G, Pradip Kumar Das, Panjan Ghosh. P., Kinsuk Das S, Kalyan C., Archana Jain

Abstract


The hepatitis C virus (HCV) affects 58 million individuals globally and is a serious public health concern.  HCV  is  a  spherical, enveloped,  positive-standard  ribo nuclleic acid (RNA)  virus . It  is  a  member  of  the  family  Flavi viridae, yet distinct to be classified  as  a  separate genus. HCV is a positive-strand ribonucleic acid (RNA) virus that is spherical and encased. This article  provides an information an information regarding  etiology, Epidemiology, Patho physiolgy, Diagnosis, Differential  Diagnosis  and  Treatment. An illness caused by a virus called hepatitis C results in inflammation, or swelling of the liver. Liver damage from hepatitis C can be quite significant. Blood that carries the hepatitis C virus (HCV) in it can be shared by coming into contact with it. You may contract hepatitis C if you come into touch with blood or bodily fluids contaminated with the virus through interaction with an infected person.

                                For the majority of patients with chronic hepatitis C, or persistent infection, newer antiviral medications are the recommended course of treatment. Many times, these medications can treat chronic hepatitis C. Hepatitis C, however, is often unknown to its sufferers. This is mostly because symptoms may not show up for decades. Accordingly, the U.S. Preventive Services Task Force advises that hepatitis C screening be done on all persons between the ages of 18 and 79.


Full Text:

PDF

References


Mashiba T, Joko K, Kurosaki M, Ochi H, Hasebe C, Akahane T, Sohda T, Tsuji K, Mitsuda A, Kimura H, Narita R, Ogawa C, Furuta K, Shigeno M, Okushin H, Ito H, Kusakabe A, Satou T, Kawanami C, Nakata R, Kobashi H, Tamada T, Ide Y, Yagisawa H, Morita A, Matsushita T, Okada K, Izumi N. Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatol Res. 2019 Oct;49(10):1114-1120. [PMC free article] [PubMed]

Morales- Arraez D, Alonso-Larruga A, Diaz-Flores F, García Dopico JA, de Vera A, Quintero E, Hernández-Guerra M. Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. J Viral Hepat. 2019 Sep;26(9):1117-1123. [PubMed]

Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell'Unto C, Lai Q, Cabibbo G, Sacco R, Villa E, Trevisani F. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf. 2019 Jul;18(7):603-610. [PubMed]

Kamimura K, Sakamaki A, Kamimura H, Setsu T, Yokoo T, Takamura M, Terai S. Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. World J Gastroenterol. 2019 Apr 21;25(15):1817-1827. [PMC free article] [PubMed]

Parigi TL, Torres MCP, Aghemo A. Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure. Clin Mol Hepatol. 2019 Dec;25(4):360-365. [PMC free article] [PubMed]

Mukhtar NA, Ness EM, Jhaveri M, Fix OK, Hart M, Dale C, Pratt C, Kowdley KV. Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. Ann Hepatol. 2019 Mar-Apr;18(2):360-365. [PubMed]

Soi V, Daifi C, Yee J, Adams E. Pathophysiology and Treatment of Hepatitis B and C Infections in Patients With End-Stage Renal Disease. Adv Chronic Kidney Dis. 2019 Jan;26(1):41-50. [PubMed]

Simoncini GM, Koren DE. Hepatitis C Update and Expanding the Role of Primary Care. J Am Board Fam Med. 2019 May-Jun;32(3):428-430. [PubMed]

Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct J. 2019 May 09;16(1):32. [PMC free article] [PubMed]

Lam JO, Hurley LB, Chamberland S, Champsi JH, Gittleman LC, Korn DG, Lai JB, Quesenberry CP, Ready J, Saxena V, Seo SI, Witt DJ, Silverberg MJ, Marcus JL. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system. Int J STD AIDS. 2019 Jun;30(7):689-695. [PMC free article] [PubMed]

Genotype 4: Northern Africa and the Middle East.

Genotype 5: South Africa

Genotype 6: Southeast Asia.

Genotype 7: Central Africa (Congo)

Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. (2000). Pathogenesis,

natural history, treatment, and prevention of hepatitis C. Annals of internal medicine,

(4), 296-305.

Manns, M. P., Buti, M., Gane, E. D., Pawlotsky, J. M., Razavi, H., Terrault, N., &

Younossi, Z. (2017). Hepatitis C virus infection. Nature reviews Disease primers,

(1), 1-19.

Ferri, C., Ramos-Casals, M., Zignego, A. L., Arcaini, L., Roccatello, D., Antonelli,

A., ... & Cacoub, P. (2016). International diagnostic guidelines for patients with HCV-

related extrahepatic manifestations. A multidisciplinary expert statement.

Autoimmunity reviews, 15(12), 1145-1160.

Jacobson, I. M., Cacoub, P., Dal Maso, L., Harrison, S. A., & Younossi, Z. M. (2010)

Manifestations of chronic hepatitis C virus infection beyond the liver. Clinical

Gastroenterology.and Hepatology, 8(12), 1017-1029.

Mandac, J. C., Chaudhry, S., Sherman, K. E., & Tomer, Y. (2006). The clinical and

physiological spectrum of interferon‐alpha induced thyroiditis: toward a new

classification. Hepatology, 43(4), 661-672.


Refbacks

  • There are currently no refbacks.